Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma

Oncology Reports

Volumn 19, Issue 5, 2008, Pages 1293-1298

  Fujiwara, Kazuko ^a   Enomoto, Takayuki ^a   Fujita, Masami ^a   Kanda, Takayoshi ^b   Fujii, Shingo ^c,i   Ito, Kimihiko ^d   Wakasa, Kenichi ^e   Ishiko, Osamu ^e   Ueda, Masatsugu ^f,j   Yamaguchi, Satoshi ^g   Kimura, Tadashi ^a   Umesaki, Naohiko ^h  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KANSAI ROSAI HOSPITAL   (Japan)

^e OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f OSAKA MEDICAL COLLEGE   (Japan)

^g HYOGO CANCER CENTER   (Japan)

^h WAKAYAMA MEDICAL UNIVERSITY   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^j Osaka Cancer Prevention and Detection Center   (Japan)

more..

Author keywords

Endometrial carcinoma; K ras; Mutation; p53; Tamoxifen

Indexed keywords

K RAS PROTEIN; PROTEIN P53; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DRUG EXPOSURE; ENDOMETRIUM CARCINOMA; EXON; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MENOPAUSE; MISSENSE MUTATION; MOLECULAR CLONING; MOLECULAR DYNAMICS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPECTROSCOPY; TREATMENT DURATION; CARCINOMA; CHEMICALLY INDUCED DISORDER; ENDOMETRIUM TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MUTATION; ONCOGENE RAS; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RAS; HUMANS; MIDDLE AGED; MUTATION; TAMOXIFEN;

EID: 47549112904     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.5.1293     Document Type: Article

References (29)

1. Blaustein A and Kurman RJ: Endometrial carcinoma. In: Blaustein's Pathology of the Female Genital Tract. Kurman RJ (ed.) Springer-Verlag, New York, pp502-503, 2002.
2. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117-126, 1989.
3. Cuzick J, Powles T, Veronesi U, et al: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296-300, 2003.
4. Stygar D, Muravitskaya N, Eriksson B, Eriksson H and Sahlin L: Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus. Reprod Biol Endocrinol 1: 40, 2003.
5. Kim SY, Suzuki N, Laxmi YR and Shibutani S: Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab Rev 36: 199-218, 2004.
6. Greaves P, Goonetilleke R, Nunn G, Topham J and Orton T: Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53: 3919-3924, 1993.
7. Carthew P, Edwards RE, Nolan BM, et al: Tamoxifen induces endometrial and vaginal cancer in rats in the absence of endometrial hyperplasia. Carcinogenesis 21: 793-797, 2000.
8. 32P-postlabeling. Cancer Res 59: 4829-4833, 1999.
9. Shibutani S, Suzuki N, Laxmi YR, et al: Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Res 63: 4402-4406, 2003.
10. Schild LJ, Divi RL, Beland FA, et al: Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days. Cancer Res 63: 5999-6003, 2003.
11. Shibutani S, Suzuki N, Terashima I, Sugarman SM, Grollman AP and Pearl ML: Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem Res Toxicol 12: 646-653, 1999.
12. Brown K, Brown JE, Martin EA, Smith LL and White IN: Determination of DNA damage in F344 rats induced by geometric isomers of tamoxifen and analogues. Chem Res Toxicol 11: 527-534, 1998.
13. Terashima I, Suzuki N and Shibutani S: Mutagenic potential of alpha-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res 59: 2091-2095, 1999.
14. Davies R, Gant TW, Smith LL and Styles JA: Tamoxifen induces G:C→T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5′CpG-3′ dinucleotide sequences as found in the lacI transgene. Carcinogenesis 20: 1351-1356, 1999.
15. Prasad M, Wang H, Douglas W, Barakat RR and Ellenson LH: Molecular genetic characterization of tamoxifen-associated endometrial cancer. Gynecol Oncol 96: 25-31, 2005.
16. Hachisuga T, Miyakawa T, Tsujioka H, Horiuchi S, Emoto M and Kawarabayashi T: K-ras mutation in tamoxifen-related endometrial polyps. Cancer 98: 1890-1897, 2003.
17. Wallen M, Tomas E, Visakorpi T, Holli K and Maenpaa J: Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene. Cancer Chemother Pharmacol 55: 343-346, 2005.
18. Enomoto T, Fujita M, Inoue M, et al: Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 53: 1883-1888, 1993.
19. Mammas IN, Zafiropoulos A and Spandidos DA: Involvement of the ras genes in female genital tract cancer. Int J Oncol 26: 1241-1255, 2005.
20. Enomoto T, Inoue M, Perantoni AO, et al: K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 51: 5308-5314, 1991.
21. Wada H, Enomoto T, Fujita M, et al: Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 57: 5379-5385, 1997.
22. Enomoto T, Fujita M, Inoue M, Nomura T and Shroyer KR: Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado: Am J Clin Pathol 103: 224-230, 1995.
23. IARC P53 Mutation Database, R11 release, October, 2006.
24. Hussain SP and Harris CC: p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res 428: 23-32, 1999.
25. Cohen I, Bernheim J, Azaria R, Tepper R, Sharony R and Beyth Y: Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 75: 136-141, 1999.
26. Barakat RR, Wong G, Curtin JP, Vlamis V and Hoskins WJ: Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 55: 164-168, 1994.
27. Senkus-Konefka E, Konefka T and Jassem J: The effects of tamoxifen on the female genital tract. Cancer Treat Rev 30: 291-301, 2004.
28. Silva EG, Tornos CS and Follen-Mitchell M: Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 13: 248-258, 1994.
29. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J and van Leeuwen FE: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356: 881-887, 2000.